Related Experiment Video
Updated: Jan 23, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
Effects of MDMA on neuroplasticity, amyloid burden and phospho-tau expression in APPswe/PS1dE9 mice
Sonia Abad1, Carla Ramon-Duaso1, Raúl López-Arnau1
1Unitat de Farmacologia I Farmacognòsia, Facultat de Farmàcia, Institut de Biomedicina IBUB, Universitat de Barcelona, Barcelona, Spain.
Background:
3,4-Methylenedioxymethamphetamine (MDMA) is still one of the most consumed drugs by adolescents. Its abuse is related with cognitive impairment, which seems due to maladaptive plasticity and neural stress. In turn, new hypotheses suggest that Alzheimer's disease (AD) may be promoted by neural stressors.
Aims And Methods:
To test if there is an increase in vulnerability to AD after chronic MDMA consumption, we investigated the effects of this drug on recognition memory and its neurotoxic and neuroplastic effects in a transgenic mouse model of presymptomatic familiar AD (APP/PS1 dE9, Tg).
Results:
MDMA-treated animals showed recognition memory deficits, regardless of genotype, which were accompanied by changes in plasticity markers. Tg mice showed an impaired expression of Arc compared with wild-type animals, but exposure to MDMA induced an increase in the expression of this factor of the same percentage in both genotypes. However, the expression of c-fos, BDNF and p-CREB was not significantly altered by MDMA treatment in Tg mice. Although Tg mice had higher free choline levels than wild-type mice (about 123%), MDMA did not modify these levels in any case, ruling out any specific effect of this drug on the acetylcholine pathway. MDMA treatment significantly increased the presence of cortical amyloid plaques, as well as Aβ40, Aβ42 and secreted APPβ levels in Tg mice. These plaques were accompanied by increased tau phosphorylation (S199), which does not seem to occur via the canonic pathway involving AKT, CDK5 or GSK3β.
Conclusions:
The present results support previous evidences that MDMA can contribute to the amyloid cascade.
Insights
Adolescent 3,4-Methylenedioxymethamphetamine (MDMA) use may increase Alzheimer's disease (AD) risk. MDMA exposure worsened memory deficits and promoted amyloid plaque formation in a mouse model, suggesting it contributes to AD pathology.
Area of Science:
- Neuroscience
- Pharmacology
- Neurodegenerative Diseases
Background:
- Adolescent 3,4-Methylenedioxymethamphetamine (MDMA) use is prevalent and linked to cognitive impairment.
- MDMA-induced neural stress and maladaptive plasticity may increase vulnerability to neurodegenerative conditions like Alzheimer's disease (AD).
- Emerging hypotheses suggest neural stressors can promote AD development.
Purpose of the Study:
- To investigate if chronic MDMA consumption increases vulnerability to Alzheimer's disease (AD).
- To examine MDMA's effects on recognition memory in a transgenic AD mouse model.
- To assess MDMA's neurotoxic and neuroplastic impacts in presymptomatic AD mice.
Main Methods:
- Utilized a transgenic mouse model of preclinical Alzheimer's disease (APP/PS1 dE9, Tg).
- Administered MDMA chronically to assess impacts on recognition memory and neural markers.
- Measured expression of plasticity markers (Arc, c-fos, BDNF, p-CREB), free choline levels, amyloid plaques, Aβ peptides, and tau phosphorylation.
Main Results:
- MDMA-treated mice exhibited recognition memory deficits, irrespective of AD-related genotype.
- MDMA significantly increased cortical amyloid plaques, Aβ40, Aβ42, and secreted APPβ levels in Tg mice.
- MDMA also increased tau phosphorylation (S199) in Tg mice, independent of canonical pathways.
Conclusions:
- Chronic MDMA consumption exacerbates AD pathology in a transgenic mouse model.
- MDMA contributes to the amyloid cascade, a key feature of Alzheimer's disease.
- Findings suggest a potential link between adolescent MDMA abuse and increased AD risk.
More Related Videos
09:12Modulation of Tau Subcellular Localization as a Tool to Investigate the Expression of Disease-related Genes
Published on: December 20, 2019
12:55Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
Published on: October 10, 2017
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Neuroplasticity
Kendall's Tau Test
A τ value of +1 indicates...
Buffer Effectiveness
The buffer capacity is the amount of acid or base that can be added to a given volume...
Framing Effects